Get the Stockscreener App
10.81
6.71%
0.68
Pre-market:
10.74
-0.07
-0.65%
Biohaven Ltd stock is traded at $10.81, with a volume of 3.11M.
It is up +6.71% in the last 24 hours and up +12.25% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
See More
Previous Close:
$10.13
Open:
$9.96
24h Volume:
3.11M
Relative Volume:
1.36
Market Cap:
$1.63B
Revenue:
-
Net Income/Loss:
$-738.82M
P/E Ratio:
-1.5531
EPS:
-6.9602
Net Cash Flow:
$-610.15M
1W Performance:
-4.25%
1M Performance:
+12.25%
6M Performance:
+18.53%
1Y Performance:
-31.50%
1-Day Range:
$9.9031
$10.83
1-Week Range:
$9.9031
$12.00
52-Week Range:
$7.48
$18.57
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
10.81 | 1.53B | 0 | -738.82M | -610.15M | -6.9602 |
VRTX
Vertex Pharmaceuticals Inc
|
428.34 | 107.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
618.95 | 63.21B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
813.14 | 49.89B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.58 | 38.20B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.99 | 32.17B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Canaccord Genuity | Buy |
| Feb-06-26 | Initiated | Goldman | Buy |
| Jan-21-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-26-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Is Biohaven’s PKM2 and Autoimmune Pipeline Progress Altering The Investment Case For Biohaven (BHVN)? - simplywall.st
How (BHVN) Movements Inform Risk Allocation Models - Stock Traders Daily
Biohaven (BHVN) Tops Valuation Grades Among Small-Cap Healthcare Stocks - GuruFocus
These 10 small-cap U.S. healthcare companies carry the market's most expensive valuations - Seeking Alpha
Biohaven Starts First Human Trial of BHV-8100 for Neurological, Retinal and Inflammatory Diseases - marketscreener.com
Biohaven begins first human trial of brain-penetrant drug BHV-8100 - StreetInsider
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation - PR Newswire
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), AngioDynamics (ANGO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN) and Healthequity (HQY) - The Globe and Mail
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Goldman Sachs Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $25 - Moomoo
Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Phreesia (PHR), McKesson (MCK) and Biohaven Ltd. (BHVN) - The Globe and Mail
Biohaven (BHVN) Insider Trading Activity 2026 - MarketBeat
William Blair Maintains Biohaven(BHVN.US) With Hold Rating - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
CCORF Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Biohaven’s Opakalim Shows Strong Seizure Control and Superior Tolerability in Epilepsy Clinical Trials - Minichart
Biohaven Showcases Promising Opakalim Epilepsy Data at R&D Day - TipRanks
Biohaven reports strong opakalim seizure control and MoDE/TRAP biomarker wins ahead of pivotal trials - TradingView
Biohaven (BHVN) unveils epilepsy, Graves’ and IgA nephropathy data at 2026 R&D Day - Stock Titan
BiohavenDespite Today's Gains, I Remain Skeptical (NYSE:BHVN) - Seeking Alpha
Biohaven (BHVN) reports positive Phase 1b autoimmune data - grafa.com
Biohaven stock jumps on positive drug trial results By Investing.com - Investing.com South Africa
Biohaven stock jumps on positive drug trial results - Investing.com
Raymond James reiterates Strong Buy on Biohaven stock after positive drug trial data By Investing.com - Investing.com South Africa
Raymond James reiterates Strong Buy on Biohaven stock after positive drug trial data - Investing.com Australia
Biohaven reports positive trial data for autoimmune therapies - Investing.com UK
Biohaven reports positive trial data for autoimmune therapies By Investing.com - Investing.com Australia
Biohaven reports positive patient data for autoimmune disease drugs - StreetInsider
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy - PR Newswire
Biohaven (BHVN) Is Up 20.0% After Promising Opakalim Epilepsy Data Release Has The Bull Case Changed? - simplywall.st
BHVN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
Biohaven opakalim trial shows strong seizure control - grafa.com
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile - The AI Journal
Biohaven reports opakalim epilepsy trial data ahead of R&D day By Investing.com - Investing.com Australia
Biohaven reports opakalim epilepsy trial data ahead of R&D day - Investing.com
Biohaven shares clinical data on epilepsy drug opakalim - StreetInsider
Biohaven Reports New Clinical Data in Epilepsy With Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile - Moomoo
Trading Systems Reacting to (BHVN) Volatility - Stock Traders Daily
BofA Securities Maintains Biohaven(BHVN.US) With Hold Rating, Maintains Target Price $12 - Moomoo
Biohaven Ltd. (BHVN) Surges 7% as Shares Test Key Resistance LevelsETF Premium Discount - thelegaladvocate.com
BHVN Stock Price, Quote & Chart | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
BTIG Reiterates Biohaven (BHVN) Buy Recommendation - MSN
BHVN Stock Chart | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
[SCHEDULE 13G/A] Biohaven Ltd. Amended Passive Investment Disclosure - Stock Titan
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):